BiotechTube
InVirtuoLabs

InVirtuoLabs

Lausanne, Switzerland· Est.
invirtuolabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

InVirtuoLabs is a private, pre-clinical stage biotech leveraging a proprietary AI and simulation platform to accelerate drug discovery. The company operates a hybrid business model, developing its own internal pipeline of drug candidates while also engaging in co-development partnerships with pharmaceutical companies. With a seasoned leadership team and recognition from Swiss innovation programs, InVirtuoLabs aims to reduce the time, cost, and failure rates associated with traditional drug development.

Metabolic DisordersNeurological DisordersPulmonary Vascular Disorders

Technology Platform

Integrated AI and simulation platform combining a molecular ML engine (InVirtuoMOL), a multimodal generative AI module (InVirtuoGEN), and physics-based molecular simulations (InVirtuoSIM) to accelerate drug discovery.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The growing demand for AI-driven efficiency in drug discovery presents a massive market opportunity.
Successfully validating its platform could position InVirtuoLabs for lucrative co-development deals with large pharma and/or the advancement of high-value internal assets.
The integration of physics-based simulations with AI is a key differentiator in a crowded market, potentially leading to more reliable and novel drug candidates.

Risk Factors

The company faces significant technical risk in proving its platform can generate clinically successful drugs, not just novel compounds.
As a pre-revenue, pre-clinical startup, securing sufficient funding to reach key milestones is a persistent challenge.
Intense competition from other AI biotechs and internal efforts by large pharmaceutical companies requires continuous innovation and clear demonstration of superior value.

Competitive Landscape

InVirtuoLabs competes in the rapidly growing AI drug discovery sector against companies like Exscientia, Recursion, Insilico Medicine, and Atomwise. Its key differentiator is the deep integration of physics-based molecular simulations with generative AI and machine learning, aiming for a more grounded and explainable approach compared to pure deep-learning models. Success depends on demonstrating this integration yields better-quality leads faster.

More companies in Switzerland →